General Interest
Amid pandemic, U.S. has seen 300,000 ‘excess deaths,’ with highest rates among people of color
22 Oct, 2020 | 09:41h | UTC
Commentary on Twitter
A new @CDCMMWR estimates since January 2020, 299,000 more people have died than the typical number during the same weeks in previous years. At least 2 out of 3 excess deaths were attributed to #COVID19. Learn more: https://t.co/fg4W6u4e3C. pic.twitter.com/i9TDxrBrTV
— CDC (@CDCgov) October 20, 2020
Will Covid-19 vaccines save lives? Current trials aren’t designed to tell us
22 Oct, 2020 | 09:40h | UTCWill covid-19 vaccines save lives? Current trials aren’t designed to tell us – The BMJ
Commentaries: COVID-19 vaccine trials won’t tell us if the shots save lives, expert notes – CNN AND Coronavirus vaccine trials won’t tell us if they save lives, prevent serious illness or stop transmission – here’s why – The Conversation
Commentary on Twitter
The world is waiting on a vaccine for covid-19 that will reduce the likelihood of getting severely ill and prevent infection. Yet the current phase III trials are not actually set up to prove either, finds Peter Doshi https://t.co/BSb9WiUQXo
— The BMJ (@bmj_latest) October 21, 2020
Video consultations in primary and specialist care during the covid-19 pandemic and beyond
21 Oct, 2020 | 09:30h | UTCVideo consultations in primary and specialist care during the covid-19 pandemic and beyond – The BMJ
Dozens to be deliberately infected with coronavirus in UK ‘human challenge’ trials
21 Oct, 2020 | 09:25h | UTCDozens to be deliberately infected with coronavirus in UK ‘human challenge’ trials – Nature
Commentaries: U.K. Preparing COVID-19 Vaccine Trials That Deliberately Expose Study Subjects – NPR AND UK plan to be first to run human challenge Covid trials – BBC
Nature journals announce first open-access agreement
21 Oct, 2020 | 09:11h | UTCNature journals announce first open-access agreement – Nature
Covid-19: The global crisis — in data
20 Oct, 2020 | 01:45h | UTCCovid-19: The global crisis — in data – Financial Times
Editorial: Covid-19’s known unknowns
20 Oct, 2020 | 01:42h | UTCCovid-19’s known unknowns – The BMJ
Commentary on Twitter
If you are going to read anything today let it be this short editorial @bmj_latest https://t.co/ggvEglehJm pic.twitter.com/hyw21BcZBU
— Maarten van Smeden (@MaartenvSmeden) October 19, 2020
Meta-analysis: Evidence-based prevention of Alzheimer’s disease
20 Oct, 2020 | 01:21h | UTCCommentaries: Biggest risk factors identified to try and prevent Alzheimer’s disease – BMJ AND Systematic review finds ten lifestyle factors that clearly impact the probability of developing Alzheimer’s disease (AD) – Sharp Brains
Commentary on Twitter
Evidence-based #prevention of #Alzheimers disease https://t.co/XOMiEoMlmI via @JNNP_BMJ #dementia @perryd43 @PennilessScribe @u3Y4BDE @SanWren @lfkraus @the_scholar1 @ktanimara @drsharwood @TargetLatino @LilithResists @Joseph_Santoro @liftdupbyangels @mrtom101 @SteveDitchfield pic.twitter.com/T5hqbzmIwi
— Ian Kremer (@LEAD_Coalition) July 24, 2020
The Lancet: Latest global disease estimates reveal perfect storm of rising chronic diseases and public health failures fuelling COVID-19 pandemic
18 Oct, 2020 | 23:21h | UTCCommentaries: Global rise in chronic diseases combined with Covid-19 bodes ill for world health – CNN AND Global study shows deadly convergence of chronic disease, COVID-19 – CIDRAP
See report: NEW Special issue of The Global Burden of Disease Study 2019
Related Editorial: Global health: time for radical change? – The Lancet
WHO: Herd immunity, lockdowns and COVID-19
18 Oct, 2020 | 23:19h | UTCCoronavirus disease (COVID-19): Herd immunity, lockdowns and COVID-19 – World Health Organization
Commentary on Twitter
Herd immunity is a concept used for vaccination, in which a population can be protected from a virus if a threshold of vaccination is reached. Vaccinated people are protected from getting the disease & passing it on, breaking any chains of transmission.
👉https://t.co/X9N7zcyfOX pic.twitter.com/V22iA6OqOq
— World Health Organization (WHO) (@WHO) October 16, 2020
[Preprint] Multi-organ impairment in low-risk individuals with long COVID
18 Oct, 2020 | 23:18h | UTCMulti-organ impairment in low-risk individuals with long COVID – medRxiv
Related study (preprint): Persistent symptoms after Covid-19: qualitative study of 114 long Covid patients and draft quality criteria for services – medRxiv
Commentary on Twitter
"In a young, low-risk population with ongoing symptoms, almost 70% of individuals have impairment in 1 or more organs 4 months after initial symptoms of #SARSCoV2 infection" #LongCovid https://t.co/gPnDtacI1J by @amibanerjee1 and colleagues
via @ahandvanish<-🙏 pic.twitter.com/7mKEsQgq5l— Eric Topol (@EricTopol) October 17, 2020
New studies show reduced prevalence and severity of SARS-CoV-2 infection in ABO blood group O
18 Oct, 2020 | 23:16h | UTCStudy 1: Reduced prevalence of SARS-CoV-2 infection in ABO blood group O – Blood Advances
Commentaries: People with blood type O may have lower risk of Covid-19 infection and severe illness, two new studies suggest – CNN AND Studies offer new evidence for possible link between blood type and COVID-19 susceptibility – American Society of Hematology
NIHR dynamic review of the evidence around ongoing Covid19 symptoms (often called Long Covid)
18 Oct, 2020 | 23:14h | UTCA dynamic review of the evidence around ongoing Covid19 symptoms (often called Long Covid) – National Institute for Health Research
News Release: Living with COVID: NIHR publishes dynamic themed review into ‘ongoing COVID’
Commentaries: Coronavirus: ‘Long Covid could be four different syndromes’ – BBC AND Long covid could be four different syndromes, review suggests – The BMJ AND ‘Long COVID’ may affect multiple parts of body and mind, doctors say – Reuters
Answering key questions about COVID-19 vaccines
18 Oct, 2020 | 23:10h | UTCAnswering Key Questions About COVID-19 Vaccines – JAMA
Commentary on Twitter
Many individuals are hesitant about receiving #COVID19 vaccines. It is critical that clinicians stay well informed about emerging data so that they can help patients make sound decisions https://t.co/1QDwOKuDqc @JesseGoodmanMD @ImmunizeOrg @pharmacists
— JAMA (@JAMA_current) October 16, 2020
[Preprint] WHO SOLIDARITY trial results published; Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon do not improve outcomes in Covid-19
16 Oct, 2020 | 09:42h | UTCRepurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results – medRxiv
Commentary: Remdesivir and interferon fall flat in WHO’s megastudy of COVID-19 treatments – Science
Commentaries on Twitter
Results of the @WHO SOLIDARITY trial:
4 drugs tested in 11,266 patients with COVID in 405 hospitals in 30 countries:
– hydroxychloroquine
– lopinavir
– remdesevir
– interferonNo clear benefit of any of them on survival. https://t.co/ohtTAFaSnc pic.twitter.com/2fO9E8zs8h
— Martin Landray (@MartinLandray) October 16, 2020
This is blockbuster from @WHO: 'Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens have little or no effect on hospitalized COVID-19, as indicated by mortality, initiation of ventilation and duration of hospital stay. @medrxivpreprint https://t.co/aNGLzLL5uW pic.twitter.com/daOAMVW62u
— Harlan Krumholz (@hmkyale) October 15, 2020
Scientific consensus on the COVID-19 pandemic: we need to act now
16 Oct, 2020 | 09:41h | UTCScientific consensus on the COVID-19 pandemic: we need to act now – The Lancet
Viewpoint: Sensible medicine—balancing intervention and inaction during the COVID-19 pandemic
16 Oct, 2020 | 09:38h | UTCSensible Medicine—Balancing Intervention and Inaction During the COVID-19 Pandemic – JAMA
Author interview: Sensible Medicine—Balancing Intervention and Inaction During the COVID-19 Pandemic
Commentary on Twitter
Has #COVID19 changed how you practice #medicine?
.
More Aggressive? Gentle? Humble? or Nihilistic?
.
Check out @JAMA_current elevating a discussion of Sensible Medicine.https://t.co/IfXVktCMJb @UPMC @UPMCnews @ErinMcCreary @PittCCM @PittTweet— Christopher Seymour (@seymoc) October 15, 2020
Act now, wait for perfect evidence later, says ‘high priestess’ of U.K. COVID-19 masking campaign
16 Oct, 2020 | 09:37h | UTC
Commentary on Twitter
Profile of @trishgreenhalgh, whose laudable and herculean efforts have favorably influenced our response to the pandemic @ScienceMagazine @UniofOxford https://t.co/t4yTFgmbr2 by @EllenRuppelShel
“As scientists, our goal must be to cut through the rubbish.”— Eric Topol (@EricTopol) October 15, 2020
Researchers worldwide fight to work and teach amid COVID-19
16 Oct, 2020 | 09:35h | UTCResearchers worldwide fight to work and teach amid COVID-19 – Nature
NEW Special issue of The Global Burden of Disease Study 2019
16 Oct, 2020 | 09:31h | UTCHomepage: Global Burden of Disease Study 2019 – The Lancet
Editorial: Global health: time for radical change? – The Lancet
Commentary on Twitter
NEW Special issue of #GBDStudy 2019: 286 causes of death, 369 diseases & injuries, 87 risk factors in 204 countries & territories—data reveal how the world’s population was prepared in terms of underlying health for #COVID19 pandemic https://t.co/Af7hOlLFoJ pic.twitter.com/9kSeyB77Fv
— The Lancet (@TheLancet) October 15, 2020
IDSA Position Statement: “Herd immunity” is not an answer to a pandemic
15 Oct, 2020 | 09:31h | UTC“Herd Immunity” is Not an Answer to a Pandemic – Infectious Diseases Society of America
Commentary on Twitter
https://t.co/k15V8bMjiK via @IDSAInfo Excellent statement from @IDSAInfo & @HIVMA Presidents of why "herd immunity" is not an answer to a pandemic. These is the professional association representing > 12K specialists in infectious diseases so these are the real experts!
— Carlos del Rio (@CarlosdelRio7) October 14, 2020
Perspective: Will SARS-CoV-2 become endemic?
15 Oct, 2020 | 09:29h | UTCWill SARS-CoV-2 become endemic? – Science
Commentary on Twitter
Whether #SARSCoV2 reinfections will be commonplace and how often they will occur remain to be understood, say authors in this Perspective. They also discuss what factors could drive the resultant pattern of endemicity if reinfection does become common. https://t.co/POKQ2byTYB pic.twitter.com/FMNbB8QR6p
— Science Magazine (@ScienceMagazine) October 14, 2020
Review: The duration of infectiousness of individuals infected with SARS-CoV-2
15 Oct, 2020 | 09:26h | UTCThe duration of infectiousness of individuals infected with SARS-CoV-2 – Journal of Infection
Commentary on Twitter
🔥NEW Review🔥#COVID19 pts with mild-to-moderate illness are highly unlikely to be infectious beyond 10 ds from symptom onset , However, limited studies found that Immunocompromised and severe-to-critical patients may be infectious for >10 days https://t.co/hogXvFpPEb pic.twitter.com/fBm5Se4RBf
— Antibiotic Steward🆔 Bassam Ghanem (@ABsteward) October 13, 2020
The 4 simple reasons Germany is managing Covid-19 better than its neighbors
15 Oct, 2020 | 09:19h | UTCThe 4 simple reasons Germany is managing Covid-19 better than its neighbors – Vox
See also: The German coronavirus mystery – UnHerd
Coronavirus vaccine: What we know so far – a comprehensive guide by academic experts
15 Oct, 2020 | 09:17h | UTC